Efficacy of salmon calcitonin combined with zoledronic acid in treatment of senile primary osteoporosis
10.3760/cma.j.issn.1671-7368.2016.08.013
- VernacularTitle:鲑鱼降钙素联合唑来膦酸注射液治疗老年原发性骨质疏松症的疗效观察
- Author:
Xiaoming SHEN
;
Chenglong HUANG
;
Gang CHEN
;
Suiliang GONG
- Publication Type:Journal Article
- Keywords:
Osteoporosis;
Drug therapy
- From:
Chinese Journal of General Practitioners
2016;15(8):628-631
- CountryChina
- Language:Chinese
-
Abstract:
One hundred and twenty patients with senile primary osteoporosis were enrolled in the study from January 2012 to April 2013,including 41 males and 79 females.Patients were randomly assigned to two groups:60 patients in study group were treated with salmon calcitonin combined with zoledronic acid (salmon calcitonin 50 IU i.m,q.d for 7 d,then 100 IU q.i.d for 7 d,followed by zoledronic acid 5 mg i.v gtt/y);60 cases in control group were treated with alendronate (70 mg p.o/wk).Both groups received the same doses of calcium.Visual analogue scale (VAS) scores were assessed before,and 1,6 and 12 months after treatment,12-Item Short-Form Health Survey (SF-12) and bone mineral density (BMD) were assessed before and 12 months after treatment.There were no significant differences in all baseline parameters between two groups (P ＞ 0.05).After 1 month of treatment,the VAS scores of study group was lower than that of the control group (2.1 ± 3.0 vs.4.2 ± 3.1,P ＜ 0.05),however,both groups had similar improvements in VAS scores in 6 and 12 months after the treatment (P ＞0.05).Compared to those before treatment,physical component summary and mental component summary of SF-12 scores after 1 year of treatment were improved significantly in both groups (P ＜ 0.05).Also,BMD was significantly improved after 1 year of treatment in both groups (P ＜ 0.05).The incidence of side effect in study group was lower than that in control group (16％ vs.20％,P ＜0.05).The results indicate that salmon calcitonin combined with zoledronic acid is an effective,safe,reliable and well tolerated therapy for senile primary osteoporosis.The long-term outcomes remain to be determined.
